These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 12945473)

  • 1. Prevention of cardiovascular disease: plea for a rationale use of diet and lipid-lowering drugs.
    Scheen AJ
    Acta Clin Belg; 2003; 58(3):149-51. PubMed ID: 12945473
    [No Abstract]   [Full Text] [Related]  

  • 2. Lipid Lowering Is Beneficial for Secondary Prevention but Not Primary Prevention in Patients 75 Years and Older.
    Ebell MH
    Am Fam Physician; 2021 Jun; 103(11):695-696. PubMed ID: 34060787
    [No Abstract]   [Full Text] [Related]  

  • 3. An analysis of first authorizations for lipid-lowering drugs in Belgium.
    Devroey D; Betz W
    Acta Clin Belg; 2003; 58(3):152-8. PubMed ID: 12945474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Landmark lipid-lowering trials in the primary prevention of cardiovascular disease.
    Chrispin J; Martin SS; Hasan RK; Joshi PH; Minder CM; McEvoy JW; Kohli P; Johnson AE; Wang L; Blaha MJ; Blumenthal RS
    Clin Cardiol; 2013 Sep; 36(9):516-23. PubMed ID: 23722477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Part I. Fibrates in primary and secondary prevention].
    Clin Investig Arterioscler; 2016 Jul; 28 Suppl 3():3-10. PubMed ID: 27473465
    [No Abstract]   [Full Text] [Related]  

  • 6. Terje Pedersen: a pioneer trialist in preventive cardiology.
    Morris K
    Lancet; 2010 Feb; 375(9716):717. PubMed ID: 20189014
    [No Abstract]   [Full Text] [Related]  

  • 7. Cardiovascular risk assessment and lipid modification: NICE guideline.
    Duerden M; O'Flynn N; Qureshi N
    Br J Gen Pract; 2015 Jul; 65(636):378-80. PubMed ID: 26120133
    [No Abstract]   [Full Text] [Related]  

  • 8. Risk factors for primary prevention of cardiovascular disease and risk reduction by lipid control: the OMEGA study risk factor sub-analysis.
    Teramoto T; Kawamori R; Miyazaki S; Teramukai S; Mori Y; Okuda Y; Hiramatsu K;
    Clin Exp Hypertens; 2014; 36(4):236-43. PubMed ID: 23865387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attainment of low-density lipoprotein cholesterol target in the French general population according to levels of cardiovascular risk: Insights from the MONA LISA study.
    Bongard V; Dallongeville J; Arveiler D; Ruidavets JB; Amouyel P; Wagner A; Ferrières J
    Arch Cardiovasc Dis; 2013 Feb; 106(2):93-102. PubMed ID: 23527913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspirin for primary prevention: yes or no?
    Selak V; Elley CR; Wells S; Rodgers A; Sharpe N
    J Prim Health Care; 2010 Jun; 2(2):92-9. PubMed ID: 20690297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing dyslipidaemia for the primary prevention of cardiovascular disease.
    Ryan A; Heath S; Cook P
    BMJ; 2018 Mar; 360():k946. PubMed ID: 29572251
    [No Abstract]   [Full Text] [Related]  

  • 12. [Is there still an actual place for cardiovascular prevention in the elderly? Focus on antiplatelet and lipid lowering agents].
    Radermecker RR; Lancellotti P
    Rev Med Liege; 2014; 69(5-6):318-22. PubMed ID: 25065239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The factors that condition the efficacy of and indications for statins in cardiovascular prevention].
    Pintó Sala X
    Aten Primaria; 1999 Mar; 23(4):227-30, 232-4. PubMed ID: 10333608
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term achievement of the therapeutic objectives of lipid-lowering agents in primary prevention patients and cardiovascular outcomes: an observational study.
    Van Ganse E; Souchet T; Laforest L; Moulin P; Bertrand M; Le Jeunne P; Chretin S; Yin D; Alemao E; de Pouvourville G
    Atherosclerosis; 2006 Mar; 185(1):58-64. PubMed ID: 16038912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular primary prevention: how high should we set the bar?
    Prasad V; Vandross A
    Arch Intern Med; 2012 Apr; 172(8):656-9; discussion 659. PubMed ID: 22529231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescribing for comorbid disease in a palliative population: focus on the use of lipid-lowering medications.
    Russell BJ; Rowett D; Abernethy AP; Currow DC
    Intern Med J; 2014 Feb; 44(2):177-84. PubMed ID: 24341863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Report on the SA Hypertension Congress (7-9 March 2003): successful combination of CME and new research.
    Cardiovasc J S Afr; 2003; 14(2):103-6. PubMed ID: 12861999
    [No Abstract]   [Full Text] [Related]  

  • 18. Primary prevention of cardiovascular disease: implications of lipid-lowering trials.
    Pedersen TR
    J Hypertens Suppl; 1996 Dec; 14(5):S195-200. PubMed ID: 9120679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Views on lipid lowering. JUPITER seems to be bypassed.
    Murray SW
    BMJ; 2010 Oct; 341():c5835. PubMed ID: 20959303
    [No Abstract]   [Full Text] [Related]  

  • 20. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance.
    Rabar S; Harker M; O'Flynn N; Wierzbicki AS;
    BMJ; 2014 Jul; 349():g4356. PubMed ID: 25035388
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.